Product Code: BHL0787SB
“Global Neoantigen Cancer Vaccine Market to Reach $1,988.5 Million by 2031.”
Market Report Coverage - Neoantigen Cancer Vaccine
Market Segmentation
- Product Type - Personalized and Off-the-Shelf
- Type of Neovaccine - Nucleic Acid Vaccine, Peptide Vaccine, and Dendritic Cell-Based Vaccine
- Therapeutic Specialty - Lung Cancer, Urinary System Cancer, Melanoma, Liver Cancer, Head and Neck Cancer, and Blood and Bone Marrow Cancer
- Line of Therapy - First Line, Second Line, and Later Lines
Regional Segmentation
- North America - U.S. and Canada
- Europe - Germany, U.K., France, Italy, and Spain
- Asia-Pacific and Middle East - China, Australia, Japan, South Korea, and Israel
Market Growth Drivers
- Increasing Global Prevalence of Cancer
- Increase in Adoption of Personalized Medicine to Tailor Patient's Treatment on an Individual Level
- Significant External Funding for Executing Research and Development Exercise
Market Challenges
- Higher Cost of Personalized Cancer Vaccines
- Hurdles in Clinical Development and Optimization Process
- Uncertain Reimbursement Scenario
- Payer Uncertainty and Outcome-Based Pricing
- High Capital Requirement Hampering the Expansion of Global Reach
Market Opportunities
- Reduced Turnaround Time and Cost
- Partnerships and Collaboration between Various Healthcare Stakeholders
Key Companies Profiled
Moderna Therapeutics, F. Hoffmann-La Roche Ltd, AstraZeneca plc, Agenus, OSE Immunotherapeutics, Advaxis, Medigene, Neon Therapeutics (Acquired by BioNTech SE), Genocea Biosciences, Immunovative Therapies, Gritstone Oncology, Nouscom, NantBioScience, Immunovaccine, BioLineRx, Geneos Therapeutics.
Key Questions Answered in this Report:
- What are the major market drivers, challenges, and opportunities in the global neoantigen cancer vaccines market?
- What are the underlying structures resulting in emerging trends within the global neoantigen cancer vaccines market?
- What key development strategies are implemented by the major players in order to sustain in the competitive market?
- What are the key regulatory implications in developed and developing regions for neoantigen cancer vaccines?
- How each segment of the market is expected to grow during the forecast period 2024-2031, and what is the estimated revenue to be generated by each of the segments on the basis of:
- Product Type (Personalized and Off-the-Shelf),
- Type of Neovaccine (Nucleic Acid Vaccine, Peptide Vaccine, and Dendritic Cell-Based Vaccine)
- Line of Therapy (First Line, Second Line, and Later Lines)
- Region, including North America, Europe, Asia-Pacific and Middle East
- Who are the leading players with significant offerings to the global neoantigen cancer vaccines market? What is the expected market dominance for each of these leading players?
- Which companies are anticipated to be highly disruptive in the future and why?
- What are the current treatment gaps, and how neovaccines are expected to fill these gaps?
- What are the unmet needs in the global neoantigen cancer vaccine market?
Market Overview
The global neoantigen cancer vaccine industry analysis by BIS Research projects the market to grow at a significant CAGR of 77.73% during the forecast period 2024-2031. The neoantigen cancer vaccine market is expected to generate $35.5 million in revenue in 2024, owing to the expected launch of the first neoantigen vaccine, DC vaccine in the market.
The neoantigen cancer vaccine market growth has been primarily attributed to major drivers in this market, such as rising prevalence of cancers, increasing adoption of personalized medicine to tailor patient's treatment on an individual level, and significant external funding for executing research and development exercises. However, significant challenges are restraining the market growth. These challenges include the expected higher cost of personalized cancer vaccines, hurdles in clinical development, and payer uncertainty and outcome-based pricing.
Expert Quote on the Neoantigen Cancer Vaccine Market
"The real issues with neovaccines are higher cost, turn-around times, and limited efficacy. The cost and time to manufacture have come down in the last four years, and as technology improves, it will come down more."
The neoantigen cancer vaccine market report provides a holistic view of the market in terms of various factors influencing it, including reported clinical findings, financing and partnership opportunities, expected market, and current clinical landscape.
The scope of this report is centered upon conducting a detailed study of the products expected to be allied with the oncology market. In addition, the study also includes exhaustive information on the unmet needs, perception on the new products, competitive landscape, market share of key players, growth potential of each underlying sub segment and company, as well as other vital information with respect to the global neoantigen cancer vaccine market.
Pipeline Segmentation
- The emerging neoantigen cancer vaccines are segmented based on product type into personalized and off-the-shelf neovaccines.
- The emerging neoantigen cancer vaccines are segmented based on disease/application into lung cancer, urinary system cancer, melanoma, liver cancer, head and neck cancer, and blood and bone marrow cancer.
- The emerging neoantigen cancer vaccines are segmented based on type of neovaccine into nucleic acid vaccine, peptide vaccine, and dendritic cell vaccine.
- The emerging neoantigen cancer vaccines are segmented based on line of therapy into first, second, and later lines therapy.
- The emerging neoantigen cancer vaccines are segmented based on development phase into Phase I, II, and III.
- The emerging neoantigen cancer vaccines are segmented on the basis of route-of-administration into intradermal, subcutaneous, and intramuscular administrations.
Table of Contents
1 Product Definition
- 1.1 Inclusion and Exclusion
2 Research Scope
- 2.1 Scope of the Study
- 2.2 Key Questions Answered in the Report
3 Research Methodology
- 3.1 Primary Data Sources
- 3.1.1 Secondary Data Sources
- 3.2 Market Estimation Model
- 3.2.1 Factors for Data Prediction and Modelling
- 3.2.2 Assumptions and Limitations
4 Neoantigen Cancer Vaccine in Cancer Immunotherapy: Overview
- 4.1 Introduction
- 4.2 Cancer Antigens
- 4.3 Targeting Cancer Neoantigen: A Next Wave of Innovation in Oncology?
- 4.4 Neoantigen Cancer Vaccine Mechanism of Action
- 4.5 Types of Neoantigen Cancer Vaccine (by Product Type)
- 4.5.1 Personalized Cancer Vaccine
- 4.5.2 Off-the-Shelf Neoantigen Cancer Vaccine
- 4.6 Types of Neoantigen Cancer Vaccine Market (by Type of Neovaccine (Biological Platform))
- 4.6.1 Nucleic Acid/DNA/mRNA Vaccine
- 4.6.2 Peptide Vaccine
- 4.6.3 Dendritic Cell-Based Vaccine
- 4.7 Types of Neoantigen Cancer Vaccine (by Type of Delivery)
- 4.7.1 Lipid-Based Delivery Approaches
- 4.7.1.1 Peptide (SLP) Mediate Vaccine Delivery in Conjunction with an Adjuvant
- 4.7.1.2 Sequential Immunization of Viral Prime and RNA Boost
- 4.7.2 Direct Injection of Unformulated mRNA Vaccines Encoding Neoepitopes
- 4.7.3 Other Approaches
- 4.8 Prediction Software for Neoantigens
- 4.8.1 Limitations of Neoantigen Prediction Process
- 4.9 Limitations of Neoantigen Cancer Vaccine
- 4.9.1 Lower Tumor Mutational Burden
- 4.9.2 Neoantigens Maturity
- 4.1 Future Prospects
- 4.10.1 Multi-Epitope Vaccination
- 4.10.2 Combinatorial Regimen with Targeted Therapies
- 4.10.3 Combinatorial Regimen with Conventional Cancer Therapies
5 Industry Insights
- 5.1 Overview of Regulatory Pathway for Neoantigen Cancer Vaccine
- 5.1.1 U.S. FDA Guidelines for Biologics License Application (BLA) Submission
- 5.1.2 European Medicine Agency (EMA) Biologics License Application Process
- 5.1.2.1 Centralized Procedure
- 5.1.2.2 Decentralized Procedure
- 5.1.2.3 Mutual-Recognition Procedure
- 5.2 Regulatory Challenges
- 5.3 Successful Regulatory Strategies
- 5.4 Patent Landscape
6 Impact of COVID-19 on the Global Neoantigen Cancer Vaccine Market
7 Market Dynamics
- 7.1 Overview
- 7.2 Emerging and Current Market Trends
- 7.3 Market Drivers
- 7.3.1 Increasing Global Prevalence of Cancer
- 7.3.2 Increase in Adoption of Personalized Medicine to Tailor Patient's Treatment on an Individual Level
- 7.3.3 Significant External Funding for Executing Research and Development Exercise
- 7.4 Market Restraints
- 7.4.1 Higher Cost of Personalized Cancer Vaccines
- 7.4.2 Hurdles in Clinical Development and Optimization Process
- 7.4.3 Uncertain Reimbursement Scenario
- 7.4.4 Payer Uncertainty and Outcome-Based Pricing
- 7.4.5 High Capital Requirement Hampering the Expansion of Global Reach
- 7.5 Market Opportunities
- 7.5.1 Treatment Gaps
- 7.5.2 Reduced Turnaround Time and Cost
- 7.5.3 Partnerships and Collaboration between Various Healthcare Stakeholders
- 7.5.4 Data Analytics
8 Pipeline Landscape
- 8.1 Emerging Neoantigen Cancer Vaccine
- 8.2 Clinical Trials Heat Map
- 8.3 Pipeline Analysis
- 8.3.1 By Development Phase
- 8.3.2 By Type of Therapy
- 8.3.3 By Product Type
- 8.3.4 By Treatment Strategy
- 8.3.5 By Type of Neovaccine
- 8.3.6 By Delivery Approach
- 8.3.7 By Line of Therapy
- 8.3.8 By Therapeutic Specialty
- 8.3.9 By Route of Administration
- 8.3.10 By Core Product Status
- 8.3.11 By Neoantigen Payload
9 Global Neoantigen Cancer Vaccine Market (by Product Type)
- 9.1 Personalized Neoantigen Cancer Vaccine
- 9.2 Off-the-Shelf Neoantigen Cancer Vaccine
10 Global Neoantigen Cancer Vaccine Market (by Pipeline Product)
- 10.1 Tedopi
- 10.2 Allovax
- 10.3 DC (Dendritic Cells) Vaccine
- 10.4 ADXS-Neo
- 10.5 GEN-009
- 10.6 RG6180
11 Global Neoantigen Cancer Vaccine Market (by Type of Neovaccine)
- 11.1 Nucleic Acid (DNA/RNA Vaccine)
- 11.1.1 DNA Vaccine
- 11.1.2 RNA Vaccine
- 11.2 Peptide Vaccines
- 11.3 Dendritic Cell-Based Vaccine
12 Global Neoantigen Cancer Vaccine Market (by Line of Therapy)
- 12.1 First Line Neovaccine Regimens
- 12.2 Second Line Neovaccine Regimens
- 12.3 Later Lines Neovaccine Regimens
13 Global Neoantigen Cancer Vaccine Market (by Therapeutic Specialty), 2024-2031
- 13.1 Melanoma
- 13.2 Lung Cancer
- 13.3 Urinary System Cancer
- 13.4 Liver Cancer
- 13.5 Head and Neck Cancer
- 13.6 Blood and Bone Marrow Cancer
14 Global Neoantigen Cancer Vaccine Market (by Region)
- 14.1 Overview
- 14.2 North America
- 14.3 U.S.
- 14.3.1 Market Size and Forecast
- 14.4 Canada
- 14.4.1 Market Size and Forecast
- 14.5 Europe
- 14.5.1 Germany
- 14.5.1.1 Market Size and Forecast
- 14.5.2 France
- 14.5.2.1 Market Size and Forecast
- 14.5.3 U.K.
- 14.5.3.1 Market Size and Forecast
- 14.5.4 Italy
- 14.5.4.1 Market Size and Forecast
- 14.5.5 Spain
- 14.5.5.1 Market Size and Forecast
- 14.6 Asia-Pacific and Middle East
- 14.6.1 Japan
- 14.6.1.1 Market Size and Forecast
- 14.6.2 China
- 14.6.2.1 Market Size and Forecast
- 14.6.3 Australia
- 14.6.3.1 Market Size and Forecast
- 14.6.4 South Korea
- 14.6.4.1 Market Size and Forecast
- 14.6.5 Israel
- 14.6.5.1 Market Size and Forecast
15 Competitive Landscape
- 15.1 Overview
- 15.2 Key Developments and Strategies
- 15.2.1 Partnerships and Alliances
- 15.2.2 Business Expansions
- 15.2.3 Merger and Acquisition Activities
- 15.2.4 Product Approvals
- 15.2.5 Financing Activities
- 15.2.6 Funding Activities
- 15.2.7 Regulatory and Legal Activities
16 Company Profiles
- 16.1 Moderna Therapeutics
- 16.1.1 Company Overview
- 16.1.2 Role of Moderna Therapeutics in the Global Neoantigen Cancer Vaccine Market
- 16.1.3 Technology and Capabilities
- 16.1.4 Financials
- 16.1.5 Key Insights about Financial Health of the Company
- 16.1.6 SWOT Analysis:
- 16.2 F. Hoffmann-La Roche Ltd
- 16.2.1 Company Overview
- 16.2.2 Role of F. Hoffmann-La Roche Ltd in the Global Neoantigen Cancer Vaccine Market
- 16.2.3 Technology and Capabilities
- 16.2.3.1 Technology Platform
- 16.2.3.2 Manufacturing
- 16.2.4 Financials
- 16.2.5 Key Insights about Financial Health of the Company
- 16.2.6 SWOT Analysis:
- 16.3 AstraZeneca plc
- 16.3.1 Company Overview
- 16.3.2 Role of AstraZeneca plc in the Global Neoantigen Cancer Vaccine Market
- 16.3.3 Financials
- 16.3.4 Key Insights about Financial Health of the Company
- 16.3.5 SWOT Analysis:
- 16.4 Agenus
- 16.4.1 Company Overview
- 16.4.2 Role of Agenus in the Global Neoantigen Cancer Vaccine Market
- 16.4.3 Technology and Capabilities
- 16.4.3.1 Technology Platforms
- 16.4.3.2 Manufacturing
- 16.4.3.3 Adjuvant
- 16.4.4 Financials
- 16.4.5 Key Insights about Financial Health of the Company
- 16.4.6 SWOT Analysis:
- 16.5 OSE Immunotherapeutics
- 16.5.1 Company Overview
- 16.5.2 Role of OSE Immunotherapeutics in the Global Neoantigen Cancer Vaccine Market
- 16.5.3 Technology and Capabilities
- 16.5.3.1 Technology Platforms
- 16.5.3.2 Manufacturing
- 16.5.4 Financials
- 16.5.5 Key Insights about Financial Health of the Company
- 16.5.6 SWOT Analysis:
- 16.6 Advaxis
- 16.6.1 Company Overview
- 16.6.2 Role of Advaxis in the Global Neoantigen Cancer Vaccine Market
- 16.6.3 Technology and Capabilities
- 16.6.3.1 Technology platform
- 16.6.3.2 Manufacturing
- 16.6.4 Financials
- 16.6.5 Key Insights about Financial Health of the Company
- 16.6.6 SWOT Analysis:
- 16.7 Medigene
- 16.7.1 Company Overview
- 16.7.2 Role of Medigene in the Global Neoantigen Cancer Vaccine Market
- 16.7.3 Technology and Capabilities
- 16.7.3.1 Technology Platform
- 16.7.3.2 Manufacturing
- 16.7.4 Financials
- 16.7.5 Key Insights about Financial Health of the Company
- 16.7.6 SWOT Analysis:
- 16.8 Neon Therapeutics (Acquired by BioNTech SE)
- 16.8.1 Company Overview
- 16.8.2 Role of Neon Therapeutics (Acquired by BioNTech SE) in the Global Neoantigen Cancer Vaccine Market
- 16.8.3 Technology and Capabilities
- 16.8.3.1 Technology Platforms
- 16.8.3.2 Manufacturing
- 16.8.4 SWOT Analysis:
- 16.9 Genocea Biosciences
- 16.9.1 Company Overview
- 16.9.2 Role of Genocea Biosciences in the Global Neoantigen Cancer Vaccine Market
- 16.9.3 Technology and Capabilities
- 16.9.3.1 Technology Platform
- 16.9.3.2 Manufacturing Capabilities
- 16.9.4 SWOT Analysis:
- 16.1 Immunovative Therapies
- 16.10.1 Company Overview
- 16.10.2 Role of Immunovative Therapies in the Global Neoantigen Cancer Vaccine Market
- 16.10.3 Technology and Capabilities
- 16.10.3.1 Technology Platform
- 16.10.3.2 Manufacturing
- 16.10.4 SWOT Analysis:
- 16.11 Gritstone Oncology
- 16.11.1 Company Overview
- 16.11.2 Role of Gritstone Oncology in the Global Neoantigen Cancer Vaccine Market
- 16.11.3 Technology and Capabilities
- 16.11.3.1 Technology Platform
- 16.11.3.2 Manufacturing
- 16.11.4 SWOT Analysis:
- 16.12 Nouscom
- 16.12.1 Company Overview
- 16.12.2 Role of Nouscom in the Global Neoantigen Cancer Vaccine Market
- 16.12.3 Technology and Capabilities
- 16.12.3.1 Technology Platform
- 16.12.3.2 Manufacturing
- 16.12.4 SWOT Analysis:
- 16.13 NantBioScience
- 16.13.1 Company Overview
- 16.13.2 Role of NantBioScience in the Global Neoantigen Cancer Vaccine Market
- 16.13.3 SWOT Analysis:
- 16.14 Immunovaccine
- 16.14.1 Company Overview
- 16.14.2 Role of Immunovaccine in the Global Neoantigen Cancer Vaccine Market
- 16.14.3 SWOT Analysis:
- 16.15 BioLineRx
- 16.15.1 Company Overview
- 16.15.2 Role of BioLineRx in the Global Neoantigen Cancer Vaccine Market
- 16.15.3 SWOT Analysis:
- 16.16 Geneos Therapeutics
- 16.16.1 Company Overview
- 16.16.2 Role of Geneos Therapeutics in the Global Neoantigen Cancer Vaccine Market
- 16.16.3 SWOT Analysis: